138 related articles for article (PubMed ID: 33386332)
21. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trials.
Petersen LK; Restrepo J; Moreira ED; Iversen OE; Pitisuttithum P; Van Damme P; Joura EA; Olsson SE; Ferris D; Block S; Giuliano AR; Bosch X; Pils S; Cuzick J; Garland SM; Huh W; Kjaer SK; Bautista OM; Hyatt D; Maansson R; Moeller E; Qi H; Roberts C; Luxembourg A
Papillomavirus Res; 2017 Jun; 3():105-115. PubMed ID: 28720442
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27-45 years of age compared to women 16-26 years of age: An open-label phase 3 study.
Joura EA; Ulied A; Vandermeulen C; Rua Figueroa M; Seppä I; Hernandez Aguado JJ; Ahonen A; Reich O; Virta M; Perino A; Peris Tuser M; Peters K; Origoni M; Raspagliesi F; Tjalma WAA; Tummers P; Woelber L; Nieminen P; van Damme P; Sehouli J; Fiol Ruiz G; Brucker S; Fehm T; Cheon K; Rawat S; Luxembourg A; Wittke F
Vaccine; 2021 May; 39(20):2800-2809. PubMed ID: 33676783
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women.
Zimmerman RK; Nowalk MP; Lin CJ; Fox DE; Ko FS; Wettick E; Cost G; Hand L; Hayes J; Michaels M
J Womens Health (Larchmt); 2010 Aug; 19(8):1441-7. PubMed ID: 20629576
[TBL] [Abstract][Full Text] [Related]
24. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study.
Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER
Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial.
Donken R; Dobson SRM; Marty KD; Cook D; Sauvageau C; Gilca V; Dionne M; McNeil S; Krajden M; Money D; Kellner J; Scheifele DW; Kollmann T; Bettinger JA; Liu S; Singer J; Naus M; Sadarangani M; Ogilvie GS
Clin Infect Dis; 2020 Aug; 71(4):1022-1029. PubMed ID: 31617568
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of the 9-valent HPV vaccine in men.
Castellsagué X; Giuliano AR; Goldstone S; Guevara A; Mogensen O; Palefsky JM; Group T; Shields C; Liu K; Maansson R; Luxembourg A; Kaplan SS
Vaccine; 2015 Nov; 33(48):6892-901. PubMed ID: 26144901
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.
Krajden M; Cook D; Yu A; Chow R; Mei W; McNeil S; Money D; Dionne M; Karunakaran KP; Palefsky JM; Dobson S; Ogilvie G; Petric M
Clin Vaccine Immunol; 2011 Mar; 18(3):418-23. PubMed ID: 21248158
[TBL] [Abstract][Full Text] [Related]
28. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Valencia A; Panzer F; Chiu CH; Decreux A; Poncelet S; Karkada N; Folschweiller N; Lin L; Dubin G; Struyf F
Hum Vaccin Immunother; 2019; 15(7-8):1970-1979. PubMed ID: 31268383
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial.
Thiem VD; Quang ND; Tuan NH; Cheon K; Gallagher N; Luxembourg A; Group T; Badshah C
Hum Vaccin Immunother; 2021 Jul; 17(7):1980-1985. PubMed ID: 33844623
[TBL] [Abstract][Full Text] [Related]
30. Long intervals between two doses of HPV vaccines and magnitude of the immune response: a
Gilca V; Sauvageau C; Panicker G; De Serres G; Schiller J; Ouakki M; Unger ER
Hum Vaccin Immunother; 2019; 15(7-8):1980-1985. PubMed ID: 31017850
[TBL] [Abstract][Full Text] [Related]
31. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.
Reisinger KS; Block SL; Lazcano-Ponce E; Samakoses R; Esser MT; Erick J; Puchalski D; Giacoletti KE; Sings HL; Lukac S; Alvarez FB; Barr E
Pediatr Infect Dis J; 2007 Mar; 26(3):201-9. PubMed ID: 17484215
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.
Nygård M; Saah A; Munk C; Tryggvadottir L; Enerly E; Hortlund M; Sigurdardottir LG; Vuocolo S; Kjaer SK; Dillner J
Clin Vaccine Immunol; 2015 Aug; 22(8):943-8. PubMed ID: 26084514
[TBL] [Abstract][Full Text] [Related]
33. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose.
Lamontagne DS; Thiem VD; Huong VM; Tang Y; Neuzil KM
J Infect Dis; 2013 Oct; 208(8):1325-34. PubMed ID: 23901077
[TBL] [Abstract][Full Text] [Related]
34. Sustained Immunogenicity of 2-dose Human Papillomavirus 16/18 AS04-adjuvanted Vaccine Schedules in Girls Aged 9-14 Years: A Randomized Trial.
Huang LM; Puthanakit T; Cheng-Hsun C; Ren-Bin T; Schwarz T; Pellegrino A; Esposito S; Frenette L; McNeil S; Durando P; Rheault P; Giaquinto C; Horn M; Petry KU; Peters K; Azhar T; Hillemanns P; De Simoni S; Friel D; Pemmaraju S; Hezareh M; Thomas F; Descamps D; Folschweiller N; Struyf F
J Infect Dis; 2017 Jun; 215(11):1711-1719. PubMed ID: 28591778
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: A phase 3 open-label study.
Lv H; Wang S; Liang Z; Yu W; Yan C; Chen Y; Hu X; Fu R; Zheng M; Group T; Luxembourg A; Liao X; Chen Z
Vaccine; 2022 May; 40(23):3263-3271. PubMed ID: 35487814
[TBL] [Abstract][Full Text] [Related]
36. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years.
Schwarz TF; Huang LM; Medina DM; Valencia A; Lin TY; Behre U; Catteau G; Thomas F; Descamps D
J Adolesc Health; 2012 Feb; 50(2):187-94. PubMed ID: 22265115
[TBL] [Abstract][Full Text] [Related]
37. Antibody responses to prophylactic quadrivalent human papillomavirus vaccine at 48 months among HIV-infected girls and boys ages 9-14 in Kenya, Africa.
Mugo N; Eckert LO; Odero L; Gakuo S; Ngure K; Celum C; Baeten JM; Barnabas RV; Wald A
Vaccine; 2021 Jul; 39(33):4751-4758. PubMed ID: 33485644
[TBL] [Abstract][Full Text] [Related]
38. Antibody responses among adolescent females receiving two or three quadrivalent human papillomavirus vaccine doses at standard and prolonged intervals.
Widdice LE; Unger ER; Panicker G; Hoagland R; Callahan ST; Jackson LA; Berry AA; Kotloff K; Frey SE; Harrison CJ; Pahud BA; Edwards KM; Mulligan MJ; Sudman J; Bernstein DI
Vaccine; 2018 Feb; 36(6):881-889. PubMed ID: 29306506
[TBL] [Abstract][Full Text] [Related]
39. Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9- to 15-Year-Old Japanese Girls.
Iwata S; Murata S; Rong Han S; Wakana A; Sawata M; Tanaka Y
Jpn J Infect Dis; 2017 Jul; 70(4):368-373. PubMed ID: 28003597
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of 2 or 3 Doses of 9vHPV Vaccine in U.S. Female Individuals 15 to 26 Years of Age.
Berenson AB; Panicker G; Unger ER; Rupp RE; Kuo YF
NEJM Evid; 2024 Feb; 3(2):EVIDoa2300194. PubMed ID: 38320488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
